Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / ADS
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
19.7M
-
Shares change
-
+491K
-
Total reported value, excl. options
-
$188M
-
Value change
-
+$5.65M
-
Number of buys
-
8
-
Number of sells
-
-12
-
Price
-
$9.82
Significant Holders of Silence Therapeutics plc - ADS (SLN) as of Q3 2023
33 filings reported holding SLN - Silence Therapeutics plc - ADS as of Q3 2023.
Silence Therapeutics plc - ADS (SLN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.7M shares
.
Largest 10 shareholders include Lombard Odier Asset Management (USA) Corp (4.06M shares), Lombard Odier Asset Management (Europe) Ltd (3.44M shares), Artal Group S.A. (2.5M shares), TCG Crossover Management, LLC (2.1M shares), Deep Track Capital, LP (1.95M shares), BVF INC/IL (1.51M shares), Aquilo Capital Management, LLC (1.31M shares), Frazier Life Sciences Management, L.P. (881K shares), M28 Capital Management LP (364K shares), and GOLDMAN SACHS GROUP INC (267K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.